Zoetis Inc. (LON:0M3Q)

London flag London · Delayed Price · Currency is GBP · Price in USD
148.05
-2.51 (-1.67%)
At close: Sep 12, 2025
-1.67%
Market Cap48.47B
Revenue (ttm)6.85B
Net Income (ttm)1.91B
Shares Outn/a
EPS (ttm)4.25
PE Ratio25.42
Forward PE22.67
Dividend1.49 (1.01%)
Ex-Dividend DateJul 18, 2025
Volume5,425
Average Volume1,543
Open150.99
Previous Close150.56
Day's Range146.50 - 151.00
52-Week Range139.92 - 200.19
Beta0.89
RSI38.16
Earnings DateNov 3, 2025

About Zoetis

Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health products in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other ph... [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 1950
Employees 13,800
Stock Exchange London Stock Exchange
Ticker Symbol 0M3Q
Full Company Profile

Financial Performance

In 2024, Zoetis's revenue was $9.26 billion, an increase of 8.33% compared to the previous year's $8.54 billion. Earnings were $2.49 billion, an increase of 6.06%.

Financial numbers in USD Financial Statements

News

Zoetis: A Solid Dividend Growth Investment For The Long Haul

Zoetis leads in animal health with strong growth, innovation, and safe, fast-growing dividends—now trading near fair value. Learn why ZTS stock is a buy.

14 days ago - Seeking Alpha

Zoetis to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that a representative from the company will participate in the Morgan Stanley 23rd Annual Global Health...

19 days ago - Business Wire

Zoetis Announces Pricing of $1.85 Billion of Senior Notes

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that it has agreed to sell $1.850 billion of senior notes, consisting of $850.0 million aggregate princ...

4 weeks ago - Business Wire

If You'd Invested $1,000 in Zoetis (ZTS) Stock 10 Years Ago, Here's How Much You'd Have Today

The short-term picture has been less rosy than the longer-term one.

4 weeks ago - The Motley Fool

ZOE's Dr Federica Amati: 'Taking the Tube is the unhealthiest part of my day — the pollutants are awful'

Waking up with water, a sauna at lunchtime and putting together a healthy meal are the doctor’s wellbeing secrets

5 weeks ago - Evening Standard

Top 50 High-Quality Dividend Stocks For August 2025

My investable universe of 50 high-quality dividend growth stocks aims to identify attractive opportunities based on valuation and future return potential. Currently, 20 stocks offer an estimated futur...

5 weeks ago - Seeking Alpha

Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs

Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.

5 weeks ago - CNBC Television

Zoetis CEO: It's unclear if animal health will be a part of pharmaceutical tariffs

Kristin Peck, Zoetis CEO, joins 'Closing Bell: Overtime' to discuss Q2 earnings, tariff impact on business and domestic production.

5 weeks ago - CNBC

Zoetis Lifts Outlook As Companion Animal Portfolio Offsets Librela Decline

Animal health firm Zoetis Inc.  ZTS on Tuesday reported a second-quarter 2025 adjusted earnings per share of $1.76, up from $1.56 a year ago, beating the consensus of $1.61.

5 weeks ago - Benzinga

Zoetis Surges After Crushing Expectations And Raising Its Outlook

Zoetis stock surged early Tuesday after the animal-health company beat quarterly forecasts, leading to a guidance hike.

5 weeks ago - Investor's Business Daily

Animal healthcare firm Zoetis raises annual forecast on strong pet product demand

Zoetis raised annual forecast and beat second-quarter estimates on Tuesday, driven by strong demand for its medicines and vaccines for pets, sending the animal healthcare company's shares surging abou...

5 weeks ago - Reuters

Zoetis Announces Second Quarter 2025 Results, Raises Full Year 2025 Outlook

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2025 and raised its full year 2025 guidance. The company...

5 weeks ago - Business Wire

Zoetis Q2 2025 Earnings Preview

5 weeks ago - Seeking Alpha

Top 15 High-Growth Dividend Stocks For August 2025

My Top 15 High-Growth Dividend Stock list underperformed in July, but remains ahead of VIG and SPY year-to-date, with an 8.75% return. The watchlist targets a 12% long-term annualized return; July's l...

6 weeks ago - Seeking Alpha

How Do Investors Really Feel About Zoetis?

Zoetis's (NYSE: ZTS) short percent of float has fallen 14.56% since its last report. The company recently reported that it has 7.85 million shares sold short , which is 1.76% of all regular shares th...

7 weeks ago - Benzinga

Phibro's Feed Play Pays Off: JPMorgan Upgrades On Zoetis Deal Boost

JPMorgan upgraded Phibro Animal Health Corporation (NASDAQ: PAHC), citing strong execution following its $350 million acquisition of Zoetis' medicated feed additive and water-soluble product portfoli...

2 months ago - Benzinga

Zoetis to Host Webcast and Conference Call on Second Quarter 2025 Financial Results

PARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Tuesday, August 5, 2025. Chief Executive Officer Kristin P...

2 months ago - Business Wire